FOLFIRI regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}}FOLFIRI; FOLFIRI Regimen; FOLFIRI regimen; Folinic Acid-Fluorouracil-Irinotecan Regimen ==Overview== {{PAGENAME}} refers to a c..." |
No edit summary |
||
| Line 9: | Line 9: | ||
==Regimen== | ==Regimen== | ||
{{chemo|FOL|Leucovorin calcium (Folinic acid)}} | {{chemo|FOL|Leucovorin calcium (Folinic acid)}} | ||
| Line 19: | Line 18: | ||
==Indications== | ==Indications== | ||
*[[colorectal cancer|Metastatic colorectal cancer]]<ref name="pmid10658525">{{cite journal| author=André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP et al.| title=CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. | journal=Eur J Cancer | year= 1999 | volume= 35 | issue= 9 | pages= 1343-7 | pmid=10658525 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10658525 }} </ref> | *[[colorectal cancer|Metastatic colorectal cancer]]<ref name="pmid10658525">{{cite journal| author=André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP et al.| title=CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. | journal=Eur J Cancer | year= 1999 | volume= 35 | issue= 9 | pages= 1343-7 | pmid=10658525 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10658525 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Revision as of 17:43, 26 March 2015
|
WikiDoc Resources for FOLFIRI regimen |
|
Articles |
|---|
|
Most recent articles on FOLFIRI regimen Most cited articles on FOLFIRI regimen |
|
Media |
|
Powerpoint slides on FOLFIRI regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on FOLFIRI regimen at Clinical Trials.gov Trial results on FOLFIRI regimen Clinical Trials on FOLFIRI regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FOLFIRI regimen NICE Guidance on FOLFIRI regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FOLFIRI regimen Discussion groups on FOLFIRI regimen Patient Handouts on FOLFIRI regimen Directions to Hospitals Treating FOLFIRI regimen Risk calculators and risk factors for FOLFIRI regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FOLFIRI regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:FOLFIRI; FOLFIRI Regimen; FOLFIRI regimen; Folinic Acid-Fluorouracil-Irinotecan Regimen
Overview
FOLFIRI regimen refers to a chemotherapy regimen consisting of leucovorin calcium (calcium folinate), 5-fluorouracil, and irinotecan used in the treatment of advanced-stage and metastatic colorectal cancer.[1][2]
Regimen
FOLLeucovorin calcium (Folinic acid)
FI5-Fluorouracil
RIIrinotecan
Indications
References
- ↑ "NCI Thesaurus".
- ↑ 2.0 2.1 André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP; et al. (1999). "CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR". Eur J Cancer. 35 (9): 1343–7. PMID 10658525.